Advertisement

European Radiology

, Volume 28, Issue 11, pp 4849–4859 | Cite as

Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months

  • Stefania Rizzo
  • Francesca Botta
  • Sara Raimondi
  • Daniela Origgi
  • Valentina Buscarino
  • Anna Colarieti
  • Federica Tomao
  • Giovanni Aletti
  • Vanna Zanagnolo
  • Maria Del Grande
  • Nicoletta Colombo
  • Massimo Bellomi
Oncology
  • 329 Downloads

Abstract

Objectives

To determine if radiomic features, alone or combined with clinical data, are associated with residual tumour (RT) at surgery, and predict the risk of disease progression within 12 months (PD12) in ovarian cancer (OC) patients.

Methods

This retrospective study enrolled 101 patients according to the following inclusion parameters: cytoreductive surgery performed at our institution (9 May 2007–23 February 2016), assessment of BRCA mutational status, preoperative CT available. Radiomic features of the ovarian masses were extracted from 3D structures drawn on CT images. A phantom experiment was performed to assess the reproducibility of radiomic features. The final radiomic features included in the analysis (n = 516) were grouped into clusters using a hierarchical clustering procedure. The association of each cluster’s representative radiomic feature with RT and PD12 was assessed by chi-square test. Multivariate analysis was performed using logistic regression models. P values < 0.05 were considered significant.

Results

Patients with values of F2-Shape/Compactness1 below the median, of F1- GrayLevelCooccurenceMatrix25/0-1InformationMeasureCorr2 below the median and of F1-GrayLevelCooccurenceMatrix25/-333-1InverseVariance above the median showed higher risk of RT (36%, 36% and 35%, respectively, as opposed to 18%, 18% and 18%). Patients with values of F4-GrayLevelRunLengthMatrix25/-333RunPercentage above the median, of F2 shape/Max3DDiameter below the median and F1-GrayLevelCooccurenceMatrix25/45-1InverseVariance above the median showed higher risk of PD12 (22%, 24% and 23%, respectively, as opposed to 6%, 5% and 6%). At multivariate analysis F2-Shape/Max3DDiameter remained significant (odds ratio (95% CI) = 11.86 (1.41–99.88)). To predict PD12, a clinical radiomics model performed better than a base clinical model.

Conclusion

This study demonstrated significant associations between radiomic features and prognostic factors such as RT and PD12.

Key Points

• No residual tumour (RT) at surgery is the most important prognostic factor in OC.

• Radiomic features related to mass size, randomness and homogeneity were associated with RT.

• Progression of disease within 12 months (PD12) indicates worse prognosis in OC.

• A model including clinical and radiomic features performed better than only-clinical model to predict PD12.

Keywords

Cancer Ovary Prognosis Residual tumour Disease progression 

Abbreviations

3D

Three dimensions

BRCA

Breast-related cancer antigens

CT

Computed tomography

DICOM

Digital imaging and communications in medicine

FIGO

International Federation of Gynecology and Obstetrics

OC

Ovarian cancer

PACS

Picture archiving and communication system

PD12

Progression of disease within 12 months

RT

Residual tumour

VIF

Variance inflation factors

VOI

Volume of interest

Notes

Acknowledgements

The English text has been edited by Anne Prudence Collins (Editor and Translator Medical & Scientific Publications).

Data management of patients’ data was performed by Cristiana Fodor (Data Manager; Scientific Direction, European Institute of Oncology, Milan IT).

Funding

The authors state that this work has not received any funding.

Compliance with ethical standards

Guarantor

The scientific guarantor of this publication is Stefania Rizzo.

Conflict of interest

The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Statistics and biometry

One of the authors (Sara Raimondi) has significant statistical expertise.

Informed consent

Written informed consent was obtained from all living patients in this study.

Written informed consent was waived by the institutional review board for deceased patients’ at the time of data collection.

Ethical approval

Institutional review board approval was obtained (nr. 440/16-IEO455)

Methodology

• retrospective

• observational

• performed at one institution

Supplementary material

330_2018_5389_MOESM1_ESM.doc (418 kb)
ESM 1 (DOC 418 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30CrossRefGoogle Scholar
  2. 2.
    Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259CrossRefGoogle Scholar
  3. 3.
    Chi DS, Eisenhauer EL, Lang J et al (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559Y564CrossRefGoogle Scholar
  4. 4.
    Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19:3–10CrossRefGoogle Scholar
  5. 5.
    du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115:1234–1244CrossRefGoogle Scholar
  6. 6.
    Tan DS, Rothermundt C, Thomas K et al (2008) BRCAness syndrome in ovarian cancer: a case control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26:5530–5536CrossRefGoogle Scholar
  7. 7.
    Forstner R, Sala E, Kinkel K, Spencer JA (2010) ESUR guidelines: ovarian cancer staging and follow-up. European Society of Urogenital Radiology. Eur Radiol 20:2773–2780CrossRefGoogle Scholar
  8. 8.
    Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577CrossRefGoogle Scholar
  9. 9.
    Gevaert O, Xu J, Hoang CD et al (2012) Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data–methods and preliminary results. Radiology 264:387–396CrossRefGoogle Scholar
  10. 10.
    Yamamoto S, Korn RL, Oklu R et al (2014) ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology 272:568–576CrossRefGoogle Scholar
  11. 11.
    Rizzo S, Petrella F, Buscarino V et al (2016) CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol 26:32–42CrossRefGoogle Scholar
  12. 12.
    Karlo CA, Di Paolo PL, Chaim J et al (2013) Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology 270:464–471CrossRefGoogle Scholar
  13. 13.
    Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680CrossRefGoogle Scholar
  14. 14.
    Wang J, Wu CJ, Bao ML, Zhang J, Wang XN, Zhang YD (2017) Machine learning-based analysis of MR radiomics can help to improve the diagnostic performance of PI-RADS v2 in clinically relevant prostate cancer. Eur Radiol.  https://doi.org/10.1007/s00330-017-4800-5 CrossRefGoogle Scholar
  15. 15.
    Li Y, Liu X, Xu K et al (2017) MRI features can predict EGFR expression in lower grade gliomas: a voxel-based radiomic analysis. Eur Radiol.  https://doi.org/10.1007/s00330-017-4964-z CrossRefGoogle Scholar
  16. 16.
    Huang YQ, Liang CH, He L et al (2016) Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J Clin Oncol 34:2157–2164CrossRefGoogle Scholar
  17. 17.
    Vargas HA, Veeraraghavan H, Micco M et al (2017) A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. Eur Radiol 27:3991–4001CrossRefGoogle Scholar
  18. 18.
    Qiu Y, Tan M, McMeekin S et al (2016) Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiol 57:1149–1155CrossRefGoogle Scholar
  19. 19.
    Vargas HA, Huang EP, Lakhman Y et al (2017) Radiogenomics of high-grade serous ovarian cancer: multireader multi-institutional study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group. Radiology.  https://doi.org/10.1148/radiol.2017161870 CrossRefGoogle Scholar
  20. 20.
    Zhang L, Fried DV, Fave XJ, Hunter LA, Yang J, Court LE (2015) IBEX: an open infrastructure software platform to facilitate collaborative work in radiomics. Med Phys 42:1341–1353CrossRefGoogle Scholar
  21. 21.
    DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 44:837–845CrossRefGoogle Scholar
  22. 22.
    Aletti GD, Gostout BS, Podratz KC, Cliby WA (2006) Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 100:33–37CrossRefGoogle Scholar
  23. 23.
    Aletti GD, Garbi A, Messori P et al (2017) Multidisciplinary approach in the management of advanced ovarian cancer patients: a personalised approach. Results from a specialized ovarian cancer unit. Gynecol Oncol 144:468–473CrossRefGoogle Scholar
  24. 24.
    Mittempergher L (2016) Genomic characterization of high-grade serous ovarian cancer: dissecting its molecular heterogeneity as a road towards effective therapeutic strategies. Curr Oncol Rep 18:44CrossRefGoogle Scholar
  25. 25.
    Oza AM, Castonguay V, Tsoref D et al (2011) Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol 18:S20-7PubMedGoogle Scholar
  26. 26.
    Horvath LE, Werner T, Boucher K, Jones K (2013) The relationship between tumor size and stage in early versus advanced ovarian cancer. Med Hypotheses 80:684–687CrossRefGoogle Scholar
  27. 27.
    Rizzo S, Calareso G, De Maria F, Zanagnolo V, Lazzari R, Cecconi A, Bellomi M (2013) Gynecologic tumors: how to communicate imaging results to the surgeon. Cancer Imaging 13:611–625CrossRefGoogle Scholar
  28. 28.
    Braga EA, Fridman MV, Kushlinskii NE (2017) Molecular mechanisms of ovarian carcinoma metastasis: key genes and regulatory microRNAs. Biochemistry 82:529–541PubMedGoogle Scholar
  29. 29.
    Perneger TV (1998) What’s wrong with Bonferroni adjustments. BMJ 316:1236–1238CrossRefGoogle Scholar

Copyright information

© European Society of Radiology 2018

Authors and Affiliations

  • Stefania Rizzo
    • 1
  • Francesca Botta
    • 2
  • Sara Raimondi
    • 3
  • Daniela Origgi
    • 2
  • Valentina Buscarino
    • 4
  • Anna Colarieti
    • 5
  • Federica Tomao
    • 6
  • Giovanni Aletti
    • 7
    • 8
  • Vanna Zanagnolo
    • 7
  • Maria Del Grande
    • 9
  • Nicoletta Colombo
    • 7
    • 10
  • Massimo Bellomi
    • 1
    • 8
  1. 1.Department of RadiologyEuropean Institute of OncologyMilanItaly
  2. 2.Medical PhysicsEuropean Institute of OncologyMilanItaly
  3. 3.Department of Epidemiology and BiostatisticsEuropean Institute of OncologyMilanItaly
  4. 4.Università degli Studi di Milano, Postgraduation School in RadiodiagnosticsMilanItaly
  5. 5.Dipartimento di Medicina Interna e Specialità medicheUniversità degli Studi di Roma La SapienzaRomaItaly
  6. 6.Dipartimento di scienze ginecologico ostetriche e scienze urologicheUniversità degli Studi di Roma La SapienzaRomaItaly
  7. 7.Department of Gynecologic OncologyEuropean Institute of OncologyMilanItaly
  8. 8.Department of Oncology and Hemato-OncologyUniversità degli Studi di MilanoMilanItaly
  9. 9.Oncology Institute of Southern SwitzerlandSan Giovanni HospitalBellinzonaSwitzerland
  10. 10.Gynecologic Oncology ProgramEuropean Institute of Oncology and University of Milan-BicoccaMilanItaly

Personalised recommendations